1 | M | 62 | Y | Lung, skin | Progression after 2 courses; HACA during second course |
2 | F | 55 | Y | Lung, hilar node | Stable disease for 11 mo after 1 course |
3 | M | 51 | Y | Lung, hilar node | Stable disease for 4 mo after 3 courses |
4 | M | 78 | N | Lung, hilar node, ribs | Progression after 2 courses |
5 | F | 53 | Y | Lung, liver | Stable disease for 4 mo after 3 courses |
6 | M | 41 | N | Lung, liver, bone | Stable disease after 1 course; patient received thalidomide |
7 | M | 44 | N | Lung, liver, bone | Progression |
8 | M | 51 | N | Lung | Stable disease for 8 mo after second course; HACA after second course |
9 | M | 64 | Y | Lung, bone | Progression of disease |
10 | M | 46 | Y | Lung, liver | Progression of disease 3 mo after second course |
11 | F | 63 | Y | Lung, liver, kidney bed | Progression |
12 | M | 65 | Y | Lung, bone | Progression |
13 | F | 29 | Y | Nodes | Stable disease for 8 mo after 1 course; patient currently alive |
14 | M | 64 | Y | Liver | Sepsis during treatment, precluding completion of therapy |
15 | M | 63 | Y | Lung, nodes | Stable disease; patient currently alive |